Cargando…

Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma

PURPOSE: To explore the utility of diffusion and perfusion changes in primary renal cell carcinoma (RCC) after stereotactic ablative body radiotherapy (SABR) as an early biomarker of treatment response, using diffusion weighted (DWI) and dynamic contrast enhanced (DCE) MRI. METHODS: Patients enrolle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reynolds, Hayley M., Parameswaran, Bimal K., Finnegan, Mary E., Roettger, Diana, Lau, Eddie, Kron, Tomas, Shaw, Mark, Chander, Sarat, Siva, Shankar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095575/ https://www.ncbi.nlm.nih.gov/pubmed/30114235 http://dx.doi.org/10.1371/journal.pone.0202387

Ejemplares similares

Technical know‐how in stereotactic ablative radiotherapy (SABR)
por: Lo, Simon S., et al.
Publicado: (2016)

Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists
por: Li, Shan, et al.
Publicado: (2020)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy
por: Hardcastle, Nicholas, et al.
Publicado: (2019)

Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
por: Goldsmith, Christy, et al.
Publicado: (2012)

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
por: Olson, Robert, et al.
Publicado: (2018)

Quantification of interplay and gradient effects for lung stereotactic ablative radiotherapy (SABR) treatments
por: Tyler, Madelaine K.
Publicado: (2016)

Stereotactic ablative radiotherapy (SABR) for recurrent and previously irradiated head and neck cancers
por: Anand, Anil Kumar, et al.
Publicado: (2020)

On the reduction of aperture complexity in kidney SABR
por: Gaudreault, Mathieu, et al.
Publicado: (2021)

Restricted bowel loop contouring: Improving efficiency in radiotherapy contouring for abdomino-pelvic Stereotactic Ablative Radiotherapy (SABR)
por: Clarke, Eleanor, et al.
Publicado: (2020)

Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR)
por: Nicolae, Alexandru, et al.
Publicado: (2015)

Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia
por: Ghandourh, Wsam, et al.
Publicado: (2022)

Assessing organ at risk position variation and its impact on delivered dose in kidney SABR
por: Gaudreault, Mathieu, et al.
Publicado: (2022)

Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results
por: Boda-Heggemann, Judit, et al.
Publicado: (2012)

Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
por: Comito, Tiziana, et al.
Publicado: (2014)

Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors
por: Binkley, Michael S., et al.
Publicado: (2016)

HIF-1α Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR)
por: Song, Chang W., et al.
Publicado: (2022)

Volumetric modulated arc therapy (VMAT) comparison to 3D‐conformal technique in lung stereotactic ablative radiotherapy (SABR)
por: Mark, Frances, et al.
Publicado: (2022)

Independent review of 4DCT scans used for SABR treatment planning
por: Antony, Rachitha, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
por: Palma, David A, et al.
Publicado: (2012)

Developing a class solution for Prostate Stereotactic Ablative Body Radiotherapy (SABR) using Volumetric Modulated Arc Therapy (VMAT)
por: Murray, Louise J., et al.
Publicado: (2014)

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
por: Palma, David A., et al.
Publicado: (2020)

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II
por: Siva, Shankar, et al.
Publicado: (2018)

Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity
por: Goldsmith, Christy, et al.
Publicado: (2018)

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)
por: Dhaliwal, Inderdeep, et al.
Publicado: (2022)

Stereotactic ablative body radiotherapy (SABR) lung fractionations locally in the COVID-19 era and the impact on dosimetry, resources, early toxicities, and the environment
por: Phelps, Lyndsey, et al.
Publicado: (2021)

Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens
por: Siva, Shankar, et al.
Publicado: (2016)

To gate or not to gate - dosimetric evaluation comparing Gated vs. ITV-based methodologies in stereotactic ablative body radiotherapy (SABR) treatment of lung cancer
por: Kim, Joshua, et al.
Publicado: (2016)

Treatment-related neuroendocrine prostate cancer managed with partial stereotactic ablative radiotherapy (P-SABR) for long-term survival: a case series
por: Qi, Xin, et al.
Publicado: (2023)

Treatment Time Optimization in Single Fraction Stereotactic Ablative Radiation Therapy: A 10-Year Institutional Experience
por: Gaudreault, Mathieu, et al.
Publicado: (2022)

Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancer
por: Maia, Fernando Henrique de Albuquerque, et al.
Publicado: (2023)

Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
por: Hardcastle, Nicholas, et al.
Publicado: (2021)

Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases
por: Sogono, Paolo, et al.
Publicado: (2021)

Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial (99m)Tc-DMSA SPECT/CT
por: Jackson, Price, et al.
Publicado: (2014)

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
por: Palma, David A., et al.
Publicado: (2019)

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
por: Olson, Robert, et al.
Publicado: (2020)

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours
por: Masucci, Giuseppe V, et al.
Publicado: (2012)

A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
por: Correa, Rohann J. M., et al.
Publicado: (2018)

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
por: Lieverse, Relinde I. Y., et al.
Publicado: (2020)

An analysis of respiratory induced kidney motion on four-dimensional computed tomography and its implications for stereotactic kidney radiotherapy
por: Siva, Shankar, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5ovvlf5qsri44mu9e9i44o56a4